Finally, SNAFIA can differentiate clinically diagnosed AD patients from normal controls by directly measuring the expression level of CAP1 protein in tear fluid through enzyme-free fluorescence signal amplification and a simple test workflow. Here, CAP1 is linked to Alzheimer disease.